Recombinant Human EGF is an oligopeptide protein with a molecular weight of 6.2 kDa. It stimulates the growth and proliferation of epidermal and ectodermal cells. Recombinant Human EGF is highly pure and biologically active, and has a low endotoxin level. It is a 0.2 um filtered solution with an effective concentration of 20 pg/mL (EC50). It stimulates ectodermal progenitor cell proliferation, and stimulates the differentiation of many types of cells. It is also used for research and development purposes.
Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/4515
Thermo Fisher Scientific, FUJIFILM Irvine Scientific, Inc., ScienCell Research Laboratories, R&D Systems, Abcam PLC, Cell Sciences, Inc., Eurofins DiscoverX, PeproTech, Inc., RayBiotech, Inc., Prospec-Tany TechnoGene Ltd., Miltenyi Biotec, Tonbo Biosciences, BioLegend, Inc., EnQuire BioReagents, STEMCELL Technologies Inc., Cell Guidance Systems Ltd., Creative BioMart, Sino Biological Inc., and BioVision, Inc.
Increasing number of research and development programs in Recombinant Human EGF is driving growth of the market. For instance, in July 2020, Ocean University of China, and Luoyang Normal University, China developed a new delivery system using nanoparticles for the delivery of recombinant human EGF to the wound site. This novel system helps in improving bioavailability of EGF at the wound site and also help in maintaining its sustained release.
Growing cases of chronic wound is fostering growth of the Recombinant Human EGF market. According to the U.S. National Library of Medicine, overall, in the United States ∼2% of the total population are estimated to be affected by chronic wounds. The impact of chronic wounds is also adverse worldwide. For example, a 2016 report from Wales estimated a 6% prevalence of chronic wounds with a 5.5% cost to the National Health Service (NHS)
Apply Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/4515
Covid-19 Impact Analysis
The spread of Covid-19 has impacted the entire supply chain of the biotechnology industry due to travel restriction. There was decline in non-emergency surgeries and procedures such. According to the National Centre for Biotechnology Information (NCBI), in 2020, the total number of outpatient department treatment (OPD) visits decreased by 96.6% at a tertiary-care ophthalmology institute in Tamil Nadu, India. This was due to the national lockdown, which led to the restriction of movement that further resulted in decreased OPD visits as compared to 2019.
- The Recombinant Human EGF market is expected to exhibit a CAGR of 9.3 % over the forecast period owing to the increasing expenditure on biotechnology industry.
- North America is expected to witness significant growth over the forecast period owing to the increasing use of recombinant human EGF in cosmetic industry.
Direct Purchase This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/4515
Reasons to Buy this Recombinant Human EGF Market Report
➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Recombinant Human EGF Market
➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Recombinant Human EGF Market
➡Leading company profiles reveal details of key Recombinant Human EGF Market players emerging five operations and financial performance
➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging Recombinant Human EGF Market with five year historical forecasts
➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Recombinant Human EGF Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Recombinant Human EGF Industry Impact
Chapter 2 Global Recombinant Human EGF Competition by Types, Applications, and Top Regions and Countries
2.1 Global Recombinant Human EGF (Volume and Value) by Type
2.3 Global Recombinant Human EGF (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Recombinant Human EGF Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Recombinant Human EGF Market Analysis
Chapter 6 East Asia Recombinant Human EGF Market Analysis
Chapter 7 Europe Recombinant Human EGF Market Analysis
Chapter 8 South Asia Recombinant Human EGF Market Analysis
Chapter 9 Southeast Asia Recombinant Human EGF Market Analysis
Chapter 10 Middle East Recombinant Human EGF Market Analysis
Chapter 11 Africa Recombinant Human EGF Market Analysis
Chapter 12 Oceania Recombinant Human EGF Market Analysis
Chapter 13 South America Recombinant Human EGF Market Analysis
Chapter 14 Company Profiles and Key Figures in Recombinant Human EGF Business
Chapter 15 Global Recombinant Human EGF Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027